Proprietary Genome Editing Platforms

March 16, 2018

Companies covered: Sangamo Therapeutics, Inc. (NASDAQ:SGMO), Novartis AG (NYSE:NVS), Gilead Sciences, Inc. (NASDAQ:GILD), bluebird bio, Inc. (NASDAQ:BLUE), Cellectis S.A. (NASDAQ:CLLS), Monsanto Company (NYSE:MON), Illumina, Inc. (NASDAQ:ILMN), Foundation Medicine, Inc. (NASDAQ:FMI), CRISPR Therapeutics AG (NASDAQ:CRSP), uniQure N.V. (NASDAQ:QURE), Spark Therapeutics, Inc. (NASDAQ:ONCE), AveXis Inc (NASDAQ:AVXS), BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), Regenxbio Inc (NASDAQ:RGNX), Oxford BioMedica plc (LON:OXB), Editas Medicine (NASDAQ:EDIT), Intellia Therapeutics (NASDAQ:NTLA), GenSight Biologics SA (EPA:SIGHT), ToolGen (KONEX:199800), Lysogene SA (EPA:LYS), Applied Genetic Technologies Corporation (NASDAQ:AGTC), Adaptimmune Therapeutics plc (NASDAQ:ADAP), Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), Intrexon Corporation (NYSE:XON), Pfizer, Inc. (NYSE:PFE), Celgene Corporation (NASDAQ:CELG), Sarepta Therapeutics, Inc. (NASDAQ:SRPT), Solid Biosciences (NASDAQ:SLDB), Rocket Pharmaceuticals (NASDAQ:RCKT), Audentes Therapeutics (NASDAQ:BOLD), Fibrocell Science Inc (NASDAQ:FCSC)

Buy ($175)